JG
CPRX

Joel Greenblatt’s Catalyst Pharmaceutical CPRX Stock Holding History

Joel Greenblatt’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
41,216
-20,155
-33% -$595K ﹤0.01% 1293
2026
Q1 		$1.52M Sell
61,371
-594
-1% -$14.2K ﹤0.01% 1188
2025
Q4 		$1.45M Sell
61,965
-79,378
-56% -$1.77M 0.01% 1145
2025
Q3 		$2.78M Buy
141,343
+31,618
+29% +$650K 0.01% 915
2025
Q2 		$2.38M Buy
109,725
+62,416
+132% +$1.47M 0.01% 870
2025
Q1 		$1.15M Buy
47,309
+8,356
+21% +$188K 0.01% 963
2024
Q4 		$813K Buy
38,953
+2,812
+8% +$60.4K 0.01% 971
2024
Q3 		$718K Buy
36,141
+2,444
+7% +$45.3K 0.01% 997
2024
Q2 		$522K Sell
33,697
-1,491
-4% -$23.2K 0.01% 1075
2024
Q1 		$561K Sell
35,188
-2,314
-6% -$34.9K 0.01% 1004
2023
Q4 		$630K Sell
37,502
-76,504
-67% -$1.05M 0.01% 920
2023
Q3 		$1.33M Buy
114,006
+3,532
+3% +$47.2K 0.03% 681
2023
Q2 		$1.48M Sell
110,474
-28,977
-21% -$417K 0.03% 641
2023
Q1 		$2.31M Buy
139,451
+120,406
+632% +$1.99M 0.06% 468
2022
Q4 		$354K Sell
19,045
-31,130
-62% -$479K 0.01% 999
2022
Q3 		$644K Buy
+50,175
New +$595K 0.02% 789
2020
Q4 		– Sell
-32,653
Closed -$97K – 1015
2020
Q3 		$97K Sell
32,653
-37,219
-53% -$146K ﹤0.01% 983
2020
Q2 		$323K Sell
69,872
-57,062
-45% -$256K 0.01% 847
2020
Q1 		$489K Buy
126,934
+90,420
+248% +$371K 0.01% 725
2019
Q4 		$137K Sell
36,514
-3,306
-8% -$15.5K ﹤0.01% 1065
2019
Q3 		$211K Buy
+39,820
New +$212K ﹤0.01% 1001

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Joel Greenblatt's CPRX Position: Q2 2026 in Review

Joel Greenblatt reduced its Catalyst Pharmaceutical (CPRX) stake by 33% in Q2 2026, selling an estimated $595K and leaving 41,216 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1293.

Joel Greenblatt first reported a position in CPRX in Q3 2019 and has held it in 21 quarters since. The position peaked at $2.78M in Q3 2025. 392 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Joel Greenblatt held 41,216 shares of Catalyst Pharmaceutical worth $1.3M as of Q2 2026.
  • Joel Greenblatt sold 20,155 Catalyst Pharmaceutical shares in Q2 2026, an estimated $595K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1293 holding.
  • Joel Greenblatt first reported a position in Catalyst Pharmaceutical in Q3 2019 and has held it in 21 quarters since.
  • Joel Greenblatt's Catalyst Pharmaceutical position peaked at $2.78M in Q3 2025.
  • 392 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.